Prevalence and blood concentrations of desoxypipradrol (2-DPMP) in drivers suspected of driving under the influence of drugs and in post-mortem cases

Forensic Science International

Volumn 226, Issue 1-3, 2013, Pages 146-151

  Kriikku, Pirkko ^a,e   Wilhelm, Lars ^b   Rintatalo, Janne ^c   Hurme, Jukka ^a   Kramer, Jan ^b,d   Ojanperä, Ilkka ^e  

^a Vita Laboratory   (Finland)

^b LADR GmbH MVZ Dr Kramer and Colleagues   (Germany)

^c National Bureau of Investigation Finland   (Finland)

^d UNIVERSITY OF LÜBECK   (Germany)

^e UNIVERSITY OF HELSINKI   (Finland)

Author keywords

2 DPMP; Designer drugs; Desoxypipradrol; DUID; LC MS MS; Post mortem toxicology

Indexed keywords

AMPHETAMINE; BENZODIAZEPINE DERIVATIVE; CENTRAL STIMULANT AGENT; DESOXYPIPRADROL; UNCLASSIFIED DRUG;

ADULT; AGE DISTRIBUTION; ARTICLE; AUTOPSY; BLOOD LEVEL; BLOOD SAMPLING; CAR DRIVING; CAUSE OF DEATH; DEATH; DRIVING UNDER THE INFLUENCE OF DRUGS; DRUG ABUSE; DRUG SCREENING; FEMALE; FINLAND; FORENSIC TOXICOLOGY; HUMAN; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; PREVALENCE; PRIORITY JOURNAL; PSYCHOMOTOR PERFORMANCE; TANDEM MASS SPECTROMETRY; TRAFFIC SAFETY; URINALYSIS; VITREOUS BODY;

EID: 84875630339     PISSN: 03790738     EISSN: 18726283     Source Type: Journal    
DOI: 10.1016/j.forsciint.2012.12.021     Document Type: Article

References (35)

1. Wohlfarth A., Weinmann W. Bioanalysis of new designer drugs. Bioanalysis 2010, 2:965-979.
2. Hill S.L., Thomas S.H.L. Clinical toxicology of newer recreational drugs. Clin. Toxicol. 2011, 49:705-719.
3. EMCDDA-Europol 2011 Annual Report on the Implementation of Council Decision 2005/387/JHA (accessed 02.05.12). http://www.emcdda.europa.eu/news/2012/2.
4. Kriikku P., Wilhelm L., Schwarz O., Rintatalo J. New designer drug of abuse: 3,4-methylenedioxypyrovalerone (MDPV). Findings from apprehended drivers in Finland. Forensic. Sci. Int. 2011, 210:195-200.
5. Karjalainen K.K., Lintonen T.P., Impinen A.O., Lillsunde P.M., Ostamo A.I. Poly-drug findings in drugged driving cases during 1977-2007. J. Subst. Use 2010, 15:143-156.
6. Tripod J., Sury E., Hoffmann K. Zentralerregende Wirkung eines Neuen Piperidinderivates. Experientia 1954, 10:261-262. (In German).
7. Maxwell R.A., Chaplin E., Batmanglidj Eckhardt E., Soares J.R., Hite G. Conformational similarities between molecular models of phenethylamine and of potent inhibitors of the uptake of tritiated norepinephrine by adrenengic nerves in rabbit aorta. J. Pharmacol. Exp. Ther. 1970, 173:158-165.
8. Ferris R.M., Tang F.L.M., Maxwell R.A. A comparison of the capacities of isomers of amphetamine, deoxypipradrol and methylphenidate to inhibit the uptake of tritiated catecholamines into rat cerebral cortex slices, synaptosomal preparations of rat cerebral cortex, hypothalamus and striatum and into adrenergic nerves of rabbit aorta. J. Pharmacol. Exp. Ther. 1972, 181:407-416.
9. Eckhardt S.B.S.B., Maxwell R.A., Ferris R.M. A structure-activity study of the transport sites for the hypothalamic and striatal catecholamine uptake systems. Mol. Pharmacol. 1981, 21:374-379.
10. Sury E., Hoffmann K. über Alkylenimin-Derivate. Piperidin-derivate mit Zentralerregender Wirkung. Helv. Chim. Acta 1954, 37:2133-2145. (In German).
11. Davidson C., Ramsey J. Desoxypipradrol is more potent than cocaine on evoked dopamine efflux in the nucleus accumbens. J. Psychopharmacol. 2012, 26:1036-1041.
12. D.A. Cooper, Future Synthetic Drugs of Abuse (accessed 08.09.11). http://loinen.i2p.to/rhodium/chemistry/future_drugs.html.
13. J.M. Corkery, S. Elliott, F. Schifano, O. Corazza, A.H. Ghodse, 2-DPMP (desoxypipradrol, 2-benzhydrylpiperidine, 2-phenylmethylpiperidine) and D2PM (diphenyl-2-pyrrolidin-2-yl-methanol, diphenylprolinol): a preliminary review, Prog. Neuropsychopharmacol. Biol. Psychiatry, published 8.6.2012 ahead of print.
14. Gussow L. Giving new meaning to 'Bed, Bath and Beyond'. Emerg. Med. News 2011, 33:10.
15. J.X. Herbert, F. Daly, J.A. Tracey, Whacked!, BMJ Lett. Published July 15, 2010. (accessed 02.11.11). http://www.bmj.com/rapid-response/2011/11/02/whacked.
16. H. Tanhua, A. Virtanen, U. Knuuti, A. Leppo, E. Kotovirta, Finland - Drug Situation 2011, Report by National Institute for Health and Welfare (THL) 62/2011. Helsinki, Finland, 2011.
17. Vaarallisen Daisy-aineen koostumus selvisi (The composition of the dangerous substance 'Daisy' was revealed), Helsingin Sanomat, 18 October 2010 (In Finnish) (accessed 19.05.11). http://www.hs.fi/kotimaa/artikkeli/Vaarallisen+Daisy-aineen+koostumus+selvisi/1135260986030.
18. Lapatto-Reiniluoto O., Tacke U., Hoppu K. Design ylettyy jo huumeisiinkin. Suomen Lääkärilehti 2011, 16-17:1398-1401. (In Finnish).
19. ACMD Report on 2-DPMP 13th September 2011 (accessed 08.08.12). http://www.homeoffice.gov.uk/publications/agencies-public-bodies/acmd1/desoxypipradrol-report?view=Binary.
20. EMCDDA-Europol 2010 Annual Report on the Implementation of Council Decision 2005/387/JHA (accessed 06.03.12). https://www.europol.europa.eu/sites/default/files/publications/emcdda-europol_annual_report_2010a.pdf.
21. Peters F.T., Drummer O.H., Musshoff F. Validation of new methods. Forensic Sci. Int. 2007, 165:216-224.
22. Peters F.T., Paul L.D., Mußhoff F., Aebi B., Auwärter V., Kraemer T., Skopp G. Anforderungen an Die Validierung von Analysenmethoden. ToxChem KrimTech 2009, 76:185-209. (In German).
23. DIN EN ISO/IEC 32645: 1994.
24. Finnish Ministry of Social Affairs and Health, Fiat 1999:52. (accessed 21.08.12). http://pre20031103.stm.fi/suomi/pao/julkaisut/nolo52/kptutk.htm.
25. de Castro A., Gergov M., Ostman P., Ojanperä I., Pelander A. Combined drug screening and confirmation by liquid chromatography time-of-flight mass spectrometry with reverse database search. Anal. Bioanal. Chem. 2012, 403:1265-1278.
26. Ojanperä I.A., Heikman P.K., Rasanen I.J. Urine analysis of 3,4-methylenedioxypyrovalerone in opioid-dependent patients by gas chromatography-mass spectrometry. Ther. Drug Monit. 2011, 33:257-263.
27. Wood D.M., Dargan P.I. Use and acute toxicity associated with the novel psychoactive substances diphenylprolinol (D2PM) and desoxypipradrol (2-DPMP). Clin. Toxicol. 2012, 50:727-732.
28. Jones A.W., Holmgren A. Abnormally high concentrations of amphetamine in blood of impaired drivers. J. Forensic. Sci. 2005, 50:1215-1220.
29. Jones A.W., Holmgren A., Kugelberg F.C. Driving under the influence of central stimulant amines: age and gender differences in concentrations of amphetamine, methamphetamine, and ecstasy in blood. J. Stud. Alcohol Drugs 2008, 69:202-208.
30. Jones A.W. Age- and gender-related differences in blood amphetamine concentrations in apprehended drivers: lack of association with clinical evidence of impairment. Addiction 2007, 102:1085-1091.
31. Silber B.Y., Papafotiou K., Croft R.J., Stough C.K.K. An evaluation of the sensitivity of the standardised field sobriety tests to detect the presence of amphetamine. Psychopharmacology (Berl) 2005, 182:153-159.
32. Toennes S.W., Kauert G.F., Steinmeyer S., Moeller M.R. Driving under the influence of drugs-evaluation of analytical data of drugs in oral fluid, serum and urine, and correlation with impairment symptoms. Forensic. Sci. Int. 2005, 152:149-155.
33. Lamers C.T., Ramaekers J.G., Muntjewerff N.D., Sikkema K.L., Samyn N., Read N.L., Brookhuis K.A., Riedel W.J. Dissociable effects of a single dose of ecstasy (MDMA) on psychomotor skills and attentional performance. J. Psychopharmacol. 2003, 17:379-387.
34. Higgins S.T., Bickel W.K., Hughes J.R., Lynn M., Capeless M.A., Fenwick J.W. Effects of intranasal cocaine on human learning, performance and physiology. Psychopharmacology (Berl) 1990, 102:451-458.
35. Rush C.R., Baker R.W., Wright K. Acute physiological and behavioral effects of oral cocaine in humans: a dose-response analysis. Drug Alcohol Depend. 1999, 55:1-12.